LXRX Financial Facts
Collaborative research: 335KSubscription and license fees: 20K
See Full Income Statement
Other long-term liabilities: 53.64M
Long-term debt: 23.83M
See Full Balance Sheet
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings
|
Expand Research on LXRX
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +28.9% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -10.3% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/3/22 | Q122 | N/A | -$0.15 | N/A | N/A | $50K | N/A | N/A | N/A | ||
| 5/5/22 |  |
Q421 | -$0.16 | -$0.16 | $0.00 | $37K | $50K | N/A |  | | Details |
| 11/3/21 | |
Q321 | -$0.16 | -$0.18 | +$0.02 | N/A | N/A | N/A | | | Details |
| 7/30/21 | |
Q221 | -$0.13 | -$0.16 | +$0.03 | $234K | $9.16M | N/A | | | Details |
5/6/21  |
|
Q121 | N/A | -$0.16 | N/A | N/A | $1.68M | N/A | N/A | N/A | |
| 3/10/21 | |
Q420 | -$0.04 | -$0.28 | +$0.24 | $200K | $110K | N/A | | | Details |
| 10/29/20 |
|
Q320 | N/A | $0.26 | N/A | N/A | $16.87M | N/A | N/A | N/A | |
| 7/30/20 | |
Q220 | -$0.65 | -$0.61 | -$0.04 | $9.2M | $8.83M | N/A | | | Details |
